Prostate Cancer Stem Cells: The Role of CD133

Cancers (Basel). 2022 Nov 5;14(21):5448. doi: 10.3390/cancers14215448.

Abstract

Prostate cancer stem cells (PCSCs), possessing self-renewal properties and resistance to anticancer treatment, are possibly the leading cause of distant metastasis and treatment failure in prostate cancer (PC). CD133 is one of the most well-known and valuable cell surface markers of cancer stem cells (CSCs) in many cancers, including PC. In this article, we focus on reviewing the role of CD133 in PCSC. Any other main stem cell biomarkers in PCSC reported from key publications, as well as about vital research progress of CD133 in CSCs of different cancers, will be selectively reviewed to help us inform the main topic.

Keywords: CD133; prostate cancer stem cells.

Publication types

  • Review

Grants and funding

This research received no external funding.